Related Experiment Video
Updated: Jun 16, 2026
08:15
Network Pharmacology and Validation of the Antidepressant Mechanisms of Qiangzhifang in a Chronic Restraint Stress-induced Depression Rat Model
Published on: June 6, 2025
The cholinergic system and depression
Girstautė Dagytė1, Johan A Den Boer, Andrea Trentani
1Department of Molecular Neurobiology, University of Groningen, The Netherlands. G.Dagyte@rug.nl
Behavioural Brain Research
|February 23, 2010
Summary
Major depressive disorder involves the cholinergic system, impacting cognition. Targeting this system may offer new treatments for depression-related cognitive impairments.
Area of Science:
- Neuroscience
- Psychiatry
Background:
- Major depressive disorder (MDD) is a significant global health burden.
- Traditional treatments focus on monoaminergic systems, but MDD's complexity remains.
- Adult hippocampal neurogenesis is increasingly recognized in MDD pathogenesis and treatment.
Purpose of the Study:
- To explore the role of the cholinergic system in major depressive disorder.
- To investigate the cholinergic system's involvement in cognitive impairments associated with depression.
- To identify potential therapeutic targets within the cholinergic system for MDD.
Main Methods:
- Review of neurobiological research on the cholinergic system and depression.
- Analysis of the link between cholinergic dysfunction and cognitive deficits in MDD.
- Examination of animal models of stress and hippocampal neurogenesis.
Main Results:
- Cholinergic system dysfunction is implicated in the pathophysiology of depression.
- Cholinergic deficits may underlie cognitive impairments observed in major depressive disorder.
- Changes in hippocampal neurogenesis in depression models may be mediated by cholinergic pathways.
Conclusions:
- The cholinergic system plays a crucial role in the cognitive symptoms of major depressive disorder.
- Cholinergic drugs show potential for treating cognitive deficits in depression.
- Further research into the cholinergic system offers insights into MDD pathophysiology and novel therapeutic strategies.
Related Concept Videos
01:30Indirect-Acting Cholinergic Agonists: Pharmacological Actions
Indirect-acting cholinergic agonists, also known as anticholinesterases, exert their pharmacological effects by enhancing cholinergic transmission in various body parts, including the neuromuscular junction, autonomic cholinergic synapses, and the brain.
At the neuromuscular junction, these agents work by inhibiting the breakdown of acetylcholine, allowing it to remain bound to the receptor and bind to nearby receptors. This process leads to repetitive firing of the endplate, causing muscle...
At the neuromuscular junction, these agents work by inhibiting the breakdown of acetylcholine, allowing it to remain bound to the receptor and bind to nearby receptors. This process leads to repetitive firing of the endplate, causing muscle...
01:18Depression: Overview
Depression is a prevalent mental illness marked by persistent sadness and lack of interest in previously enjoyable activities. It can take several forms, including major depression, persistent depressive disorder, and bipolar I and II disorders. Symptoms range from emotional changes like chronic worry to physical changes like sleep disturbances and suicidal thoughts. From a neurobiological perspective, depression is believed to be triggered by abnormalities in the brain's prefrontal cortex,...
01:28Cholinergic Antagonists: Pharmacological Actions
Antimuscarinic drugs block muscarinic receptors in multiple systems, including the gut, eye, smooth muscles, respiratory tract, cardiovascular, and central nervous systems. They produce similar effects with varying selectivity depending on the specific agent and tissue. Here are the key pharmacological actions of antimuscarinics:
Gastrointestinal Effects: Antimuscarinics reduce gut contractions, increase gastric emptying, and slow intestinal transit. They partly inhibit gastric acid secretion...
Gastrointestinal Effects: Antimuscarinics reduce gut contractions, increase gastric emptying, and slow intestinal transit. They partly inhibit gastric acid secretion...
01:30Parasympathetic Signaling
Parasympathetic signaling plays a crucial role in regulating various physiological processes. It involves the release of acetylcholine (ACh) by parasympathetic neurons, which can have localized and short-lived effects. The majority of ACh released is rapidly inactivated at the synapse by the enzyme acetylcholinesterase (AChE), which hydrolyzes Ach into choline and acetate. Additionally, the tissue cholinesterase deactivates any ACh diffusing into the surrounding tissues.
The effects of...
The effects of...
01:23Cholinergic Neurons: Neurotransmission
Cholinergic neurotransmission involves the synthesis and the release of acetylcholine (ACh) in order to transmit nerve impulses across the synapse. The process begins with the synthesis of acetyl CoA, a precursor for ACh, from ATP, acetate, and coenzyme A in the mitochondria. Choline, another vital precursor, is transported inside the neuron through choline transporters, including high-affinity choline transporter CHT1, low-affinity choline transporter CTL1, and lower-affinity choline...
00:59Direct-Acting Cholinergic Agonists: Pharmacological Actions
Direct-acting cholinergic agonists exert their pharmacological actions by mimicking the effects of acetylcholine on postsynaptic muscarinic receptors to generate parasympathetic responses. These agents elicit a range of physiological responses, including cardiovascular effects. For example, activation of muscarinic receptors induces bradycardia, decreased cardiac output, reduced peripheral resistance, and consequent hypotension. In the eye, stimulation of M3 receptors leads to smooth muscle...